nach oben

Arthritis Research & Therapy

Erschienen in:

01.12.2011 | Review

Negative regulation of NF-κB and its involvement in rheumatoid arthritis

verfasst von: Geert van Loo, Rudi Beyaert

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The transcription factor NF-κB plays crucial roles in the regulation of inflammation and mmune responses, and inappropriate NF-κB activity has been linked with many autoimmune and inflammatory diseases, including rheumatoid arthritis. Cells employ a multilayered control system to keep NF-κB signalling in check, including a repertoire of negative feedback regulators ensuring termination of NF-κB responses. Here we will review various negative regulatory mechanisms that have evolved to control NF-κB signalling and which have been implicated in the pathogenesis of rheumatoid arthritis.

Nur mit Berechtigung zugänglich

Hayden MS, Ghosh S: Shared principles in NF-κB signaling. Cell. 2008, 132: 344-362. 10.1016/j.cell.2008.01.020.CrossRef

Simmonds RE, Foxwell BM: Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008, 47: 584-590. 10.1093/rheumatology/kem298.CrossRef

Brennan FM, McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008, 118: 3537-3545. 10.1172/JCI36389.CrossRef

Roman-Blas JA, Jimenez SA: Targeting NF-κB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol. 2008, 27: 351-374. 10.1080/08830180802295740.CrossRef

Han Z, Boyle DL, Manning AM, Firestein GS: AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity. 1998, 28: 197-208. 10.3109/08916939808995367.CrossRef

Keith JC, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steff an RJ, Harnish DC: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R427-R438. 10.1186/ar1692.CrossRef

Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006, 12: 17-25. 10.1016/j.molmed.2005.11.007.CrossRef

Criswell LA: Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis. Immunol Rev. 2010, 233: 55-61. 10.1111/j.0105-2896.2009.00862.x.CrossRef

Taylor PC, Feldmann M: Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009, 5: 578-582. 10.1038/nrrheum.2009.181.CrossRef

10.

Rissoan MC, Van Kooten C, Chomarat P, Galibert L, Durand I, Thivolet-Bejui F, Miossec P, Banchereau J: The functional CD40 antigen of fi broblasts may contribute to the proliferation of rheumatoid synovium. Clin Exp Immunol. 1996, 106: 481-490. 10.1046/j.1365-2249.1996.d01-858.x.CrossRef

11.

Durie FH, Fava RA, Foy TM, Aruff o A, Ledbetter JA, Noelle RJ: Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993, 261: 1328-1330. 10.1126/science.7689748.CrossRef

12.

Kyburz D, Carson DA, Corr M: The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2571-2577. 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4.CrossRef

13.

Brown KD, Claudio E, Siebenlist U: The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 2008, 10: 212-10.1186/ar2457.CrossRef

14.

Huang QQ, Pope RM: The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep. 2009, 11: 357-364. 10.1007/s11926-009-0051-z.CrossRef

15.

Yu L, Wang L, Chen S: Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010, 14: 2592-2603. 10.1111/j.1582-4934.2010.01127.x.CrossRef

16.

Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003, 48: 2052-2058. 10.1002/art.11161.CrossRef

17.

Frosch M, Strey A, Vogl T, Wulff raat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J: Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000, 43: 628-637. 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X.CrossRef

18.

Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007, 13: 1042-1049. 10.1038/nm1638.CrossRef

19.

Vallabhapurapu S, Karin M: Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol. 2009, 27: 693-733. 10.1146/annurev.immunol.021908.132641.CrossRef

20.

Liu S, Chen ZJ: Expanding role of ubiquitination in NF-κB signaling. Cell Res. 2011, 21: 6-21. 10.1038/cr.2010.170.CrossRef

21.

Pasparakis M, Luedde T, Schmidt-Supprian M: Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ. 2006, 13: 861-872. 10.1038/sj.cdd.4401870.CrossRef

22.

Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K: Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol. 2009, 11: 123-132. 10.1038/ncb1821.CrossRef

23.

Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ: Direct activation of protein kinases by unanchored polyubiquitin chains. Nature. 2009, 461: 114-119. 10.1038/nature08247.CrossRef

24.

Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S: Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol. 2008, 9: 684-691. 10.1038/ni.1606.CrossRef

25.

Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M: Specificity in Toll-like receptor signalling through distinct eff ector functions of TRAF3 and TRAF6. Nature. 2006, 439: 204-207. 10.1038/nature04369.CrossRef

26.

Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA: Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem. 2005, 280: 36560-36566. 10.1074/jbc.M506831200.CrossRef

27.

Sun SC: Non-canonical NF-κB signaling pathway. Cell Res. 2011, 21: 71-85. 10.1038/cr.2010.177.CrossRef

28.

Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M: Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 2001, 293: 1495-1499. 10.1126/science.1062677.CrossRef

29.

Xiao G, Fong A, Sun SC: Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase alpha (IKKα) to p100 and IKKα- mediated phosphorylation. J Biol Chem. 2004, 279: 30099-30105. 10.1074/jbc.M401428200.CrossRef

30.

Peters AL, Bishop GA: Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling. J Immunol. 2010, 185: 6555-6562. 10.4049/jimmunol.1000135.CrossRef

31.

Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF: Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem. 2010, 285: 17148-17155. 10.1074/jbc.M110.105874.CrossRef

32.

Renner F, Schmitz ML: Autoregulatory feedback loops terminating the NF-κB response. Trends Biochem Sci. 2009, 34: 128-135. 10.1016/j.tibs.2008.12.003.CrossRef

33.

Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of toll-like receptormediated immune responses. Nat Rev Immunol. 2005, 5: 446-458. 10.1038/nri1630.CrossRef

34.

Lawrence T, Bebien M, Liu GY, Nizet V, Karin M: IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature. 2005, 434: 1138-1143. 10.1038/nature03491.CrossRef

35.

Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, Yang R, Mink S, Shultz D, Bellone CJ, Loo JA, Shuai K: Proinflammatory stimuli induce IKKα-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell. 2007, 129: 903-914. 10.1016/j.cell.2007.03.056.CrossRef

36.

Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, Loo JA, Cheng G: Negative feedback in noncanonical NF-κB signaling modulates NIK stability through IKKα-mediated phosphorylation. Sci Signal. 2010, 3: ra41-10.1126/scisignal.2000778.

37.

Coornaert B, Carpentier I, Beyaert R: A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2009, 284: 8217-8221.CrossRef

38.

Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature. 2004, 430: 694-699. 10.1038/nature02794.CrossRef

39.

Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA, Werts C, Ma A: The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 2008, 28: 381-390. 10.1016/j.immuni.2008.02.002.CrossRef

40.

Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, Ma A: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004, 5: 1052-1060. 10.1038/ni1110.CrossRef

41.

Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U, Darnay BG, Ruland J, Marynen P, Krappmann D: A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J Immunol. 2009, 182: 7718-7728. 10.4049/jimmunol.0803313.CrossRef

42.

Shembade N, Ma A, Harhaj EW: Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes. Science. 2010, 327: 1135-1139. 10.1126/science.1182364.CrossRef

43.

Iha H, Peloponese JM, Verstrepen L, Zapart G, Ikeda F, Smith CD, Starost MF, Yedavalli V, Heyninck K, Dikic I, Beyaert R, Jeang KT: Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-κB activation. EMBO J. 2008, 27: 629-641. 10.1038/emboj.2008.5.CrossRef

44.

Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Lohr F, Wu CJ, Ashwell JD, Dotsch V, Dikic I, Beyaert R: Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene. 2008, 27: 3739-3745. 10.1038/sj.onc.1211042.CrossRef

45.

Shembade N, Harhaj NS, Liebl DJ, Harhaj EW: Essential role for TAX1BP1 in the termination of TNF-α-, IL-1- and LPS-mediated NF-κB and JNK signaling. EMBO J. 2007, 26: 3910-3922. 10.1038/sj.emboj.7601823.CrossRef

46.

Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A: Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science. 2000, 289: 2350-2354. 10.1126/science.289.5488.2350.CrossRef

47.

Vereecke L, Sze M, Guire CM, Rogiers B, Chu Y, Schmidt-Supprian M, Pasparakis M, Beyaert R, van Loo G: Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010, 207: 1513-1523. 10.1084/jem.20092474.CrossRef

48.

Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, Ma A: The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010, 33: 181-191. 10.1016/j.immuni.2010.07.017.CrossRef

49.

Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, Soberon V, Schenten D, Mack B, Reutelshofer M, Beyaert R, Amann K, van Loo G, Schmidt-Supprian M: B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2011, 117: 2227-2236. 10.1182/blood-2010-09-306019.CrossRef

50.

Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem. 1992, 267: 17971-17976.

51.

Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, Hur GM, Lee SY, Chung MJ, Park JW, Lee SI, Park BH: A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 2010, 62: 2313-2321. 10.1002/art.27545.CrossRef

52.

Vereecke L, Beyaert R, van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30: 383-391. 10.1016/j.it.2009.05.007.CrossRef

53.

Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP: Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol. 2010, 28: 708-714.

54.

Verstrepen L, Carpentier I, Verhelst K, Beyaert R: ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol. 2009, 78: 105-114. 10.1016/j.bcp.2009.02.009.CrossRef

55.

Papoutsopoulou S, Symons A, Tharmalingham T, Belich MP, Kaiser F, Kioussis D, O'Garra A, Tybulewicz V, Ley SC: ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat Immunol. 2006, 7: 606-615.CrossRef

56.

Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, Shifrin N, Lee B, Benedict Yen TS, Woo T, Malynn BA, Ma A: ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature. 2009, 457: 906-909. 10.1038/nature07575.CrossRef

57.

Wullaert A, Verstrepen L, Van Huff el S, Adib-Conquy M, Cornelis S, Kreike M, Haegman M, El Bakkouri K, Sanders M, Verhelst K, Carpentier I, Cavaillon JM, Heyninck K, Beyaert R: LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-κB activation. J Biol Chem. 2007, 282: 81-90.CrossRef

58.

Wullaert A, Wielockx B, Van Huff el S, Bogaert V, De Geest B, Papeleu P, Schotte P, El Bakkouri K, Heyninck K, Libert C, Beyaert R: Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology. 2005, 42: 381-389. 10.1002/hep.20785.CrossRef

59.

Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, Godson C, Brady HR, Martin F: Identification of Naf1/ABIN-1 among TNF-α- induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett. 2003, 551: 8-12. 10.1016/S0014-5793(03)00823-8.CrossRef

60.

Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, Arthur JS, Kalliolias GD, Ivashkiv LB: Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity. 2010, 32: 518-530. 10.1016/j.immuni.2010.03.014.CrossRef

61.

Nair RP, Duffi n KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR: Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet. 2009, 41: 199-204. 10.1038/ng.311.CrossRef

62.

Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson AA, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, Edberg JC, Ramsey-Goldman R, McGwin G, Reveille JD, Vila LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, et al: A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009, 41: 1228-1233. 10.1038/ng.468.CrossRef

63.

Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000, 25: 160-165. 10.1038/76006.CrossRef

64.

Sun SC: CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ. 2010, 17: 25-34. 10.1038/cdd.2009.43.CrossRef

65.

Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC: Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest. 2008, 118: 1858-1866. 10.1172/JCI34257.CrossRef

66.

Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD: Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007, 117: 133-142. 10.1172/JCI28267.CrossRef

67.

Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2003, 4: 920-927. 10.1038/ni968.CrossRef

68.

McCormack WJ, Parker AE, O'Neill LA: Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther. 2009, 11: 243-10.1186/ar2729.CrossRef

69.

Polentarutti N, Rol GP, Muzio M, Bosisio D, Camnasio M, Riva F, Zoja C, Benigni A, Tomasoni S, Vecchi A, Garlanda C, Mantovani A: Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw. 2003, 14: 211-218.

70.

Drexler SK, Kong P, Inglis J, Williams RO, Garlanda C, Mantovani A, Yazdi AS, Brennan F, Feldmann M, Foxwell BM: SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 2249-2261. 10.1002/art.27517.CrossRef

71.

Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA: Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol. 2006, 176: 5388-5400.CrossRef

72.

Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, Geha RS: TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity. 2001, 15: 647-657. 10.1016/S1074-7613(01)00207-2.CrossRef

73.

Song HY, Rothe M, Goeddel DV: The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci USA. 1996, 93: 6721-6725. 10.1073/pnas.93.13.6721.CrossRef

74.

Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK: TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med. 2007, 357: 1199-1209. 10.1056/NEJMoa073491.CrossRef

75.

Chang M, Rowland CM, Garcia VE, Schrodi SJ, Catanese JJ, van der Helm-van Mil AH, Ardlie KG, Amos CI, Criswell LA, Kastner DL, Gregersen PK, Kurreeman FA, Toes RE, Huizinga TW, Seldin MF, Begovich AB: A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. PLoS Genet. 2008, 4: e1000107-10.1371/journal.pgen.1000107.CrossRef

76.

Han TU, Bang SY, Kang C, Bae SC: TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians. Arthritis Rheum. 2009, 60: 2577-2584. 10.1002/art.24759.CrossRef

77.

O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D: Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010, 10: 111-122. 10.1038/nri2708.CrossRef

78.

Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006, 103: 12481-12486. 10.1073/pnas.0605298103.CrossRef

79.

O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007, 104: 1604-1609. 10.1073/pnas.0610731104.CrossRef

80.

Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007, 179: 5082-5089.CrossRef

81.

Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 1001-1009. 10.1002/art.23386.CrossRef

82.

Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H: Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008, 58: 1284-1292. 10.1002/art.23429.CrossRef

83.

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R101-10.1186/ar2344.CrossRef

84.

Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, Fu X, Liu H, Lu L, Wu Y: Altered microRNA expression profi le with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2010, 12: R81-10.1186/ar3006.CrossRef

85.

Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, Suzuki O, Adachi N, Ochi M: MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2010, 11: 209-CrossRef

86.

Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA: A polymorphism in the 3'-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine. 2010, 77: 411-413. 10.1016/j.jbspin.2010.05.013.CrossRef

87.

Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K: Regulation of the germinal center response by microRNA-155. Science. 2007, 316: 604-608. 10.1126/science.1141229.CrossRef

88.

Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T: Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010, 12: R86-10.1186/ar3013.CrossRef

89.

Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, Chin T, Saura R, Kurosaka M, Kumagai S: MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009, 60: 1294-1304. 10.1002/art.24475.CrossRef

90.

Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D: Altered expression of miR-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 2011, 63: 373-381. 10.1002/art.30115.CrossRef

91.

Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol. 2010, 71: 206-211. 10.1016/j.humimm.2009.11.008.CrossRef

Titel: Negative regulation of NF-κB and its involvement in rheumatoid arthritis
verfasst von: Geert van Loo
Rudi Beyaert
Publikationsdatum: 01.12.2011
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 3/2011
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3324

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Negative regulation of NF-κB and its involvement in rheumatoid arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity

The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study

Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Defective response of CD4+ T cells to retinoic acid and TGFβ in systemic lupus erythematosus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin